USPTO serial 97628473
VERIPURE
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- COUGHLAN, REBECCA D.
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with VERIPURE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $648*
Plus Government fees of $300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kathleen A. Rheintgen
Kathleen A. Rheintgen Husch Blackwell LLP120 South Riverside Plaza, Suite 2200Chicago, IL 60606United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic reagents for in virology, microbiology and ophthalmology | ACTIVE | — |
| 005 | Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of tumors; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of solid tumors, namely, melanoma, breast cancer, basal cell carcinoma, prostate cancer, and small cell and non-small cell lung cancer, squamous cell carcinoma and primary and metastatic liver cancers; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of pediatric solid tumors, namely, Ewing sarcoma, neuroblastoma, osteosarcoma, neuroepithelioma, and rhabdomyosarcoma; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of leukemia; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of leukemia, namely, acute B-cell lymphoblastic leukemia, T-cell lymphoblastic leukemia, acute myeloid leukemia; Medicinal and pharmaceutical preparations, namely, pharmaceutical medications for the treatment and prevention of psoriasis; Preparations for pharmaceutical skin care; Diagnostic preparations for medical use, namely, for use in virology, microbiology, ophthalmology; Diagnostic mediums for use in virology, microbiology, ophthalmology; Pharmaceutical preparations and substances for use as vaccine adjuvants, immune system stimulators or suppressors, and immune system modulators | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 29, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 28, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 28, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 28, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 23, 2026 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Oct 23, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 23, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 23, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 16, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 16, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 16, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 16, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 24, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 21, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 21, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 21, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 21, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 29, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 4, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 4, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 26, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 10, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 12, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Feb 14, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Aug 17, 2023 | GRML | CORRESPONDENCE E-MAILED | — |
| Aug 17, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 17, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 17, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 17, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 27, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 27, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 27, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 27, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 17, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 15, 2022 | NWAP | NEW APPLICATION ENTERED | — |